29 January 2026
EMADOC-1700519818-2850511
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Efmody

hydrocortisone

On 29 January 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Efmody. The marketing authorisation holder for this medicinal product is Neurocrine Netherlands B.V.

The CHMP adopted changes to the existing indication as follows:[2]

Efmody is indicated in adolescents aged 12 years and over and adults for the:

- **Treatment of adrenal insufficiency (AI)**
- Treatment of congenital adrenal hyperplasia (CAH) ~~in adolescents aged 12 years and over and adults.~~

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summary of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
[2] New text in bold, removed text as strikethrough

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union